Not Tagged
spdr s&p biotech,ishares biotechnology,Promontory Therapeutics
['$ibb', '$xbi']
promontory therapeutics presents preliminary data from national cancer institute phase 2 trial of imifoplatin (pt-112) in treating thymoma and thymic carcinoma at 2023 asco annual meeting. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt